Sotac Pharmaceuticals

Sotac Pharmaceuticals EBITDA per Share

The EBITDA per Share of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 21, 2026 is 12.35 INR. In the previous year, EBITDA per Share was 7.49 INR — a change of 64.81% (higher).

EBITDA per Share

12.35INR

YoY

64.81%

Last updated:

EBITDA per Share of Sotac Pharmaceuticals is 2025 12.35 INR. EBITDA per Share of Sotac Pharmaceuticals was 2024 7.49 INR. It decreases by 64.81% higher compared to the previous year.

The Sotac Pharmaceuticals EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2020
1.68 INR
Jan 1, 2021
1.32 INR
Jan 1, 2022
7.21 INR
Jan 1, 2023
7.43 INR
Jan 1, 2024
7.49 INR
Jan 1, 2025
12.35 INR
The Sotac Pharmaceuticals EBITDA per Share history
YEAREBITDA per ShareYoY
12.35INR+64.81%
7.49INR+0.90%
7.43INR+2.97%
7.21INR+447.96%
1.32INR-21.87%
1.68INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

EBITDA per Share of Sotac Pharmaceuticals is 12.35 INR in 2025.

EBITDA per Share of Sotac Pharmaceuticals changed from 7.49 INR to 12.35 INR, representing a 64.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals